These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 18570608)

  • 1. Moxifloxacin: a respiratory fluoroquinolone.
    Miravitlles M; Anzueto A
    Expert Opin Pharmacother; 2008 Jul; 9(10):1755-72. PubMed ID: 18570608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Moxifloxacin in respiratory tract infections.
    Miravitlles M
    Expert Opin Pharmacother; 2005 Feb; 6(2):283-93. PubMed ID: 15757424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pharmacoeconomic review of the management of respiratory tract infections with moxifloxacin.
    Simoens S; Decramer M
    Expert Opin Pharmacother; 2008 Jul; 9(10):1735-44. PubMed ID: 18570606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Moxifloxacin: a review of its use in the management of bacterial infections.
    Keating GM; Scott LJ
    Drugs; 2004; 64(20):2347-77. PubMed ID: 15456331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections.
    Balfour JA; Lamb HM
    Drugs; 2000 Jan; 59(1):115-39. PubMed ID: 10718103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluoroquinolones in the management of community-acquired pneumonia in primary care.
    Wispelwey B; Schafer KR
    Expert Rev Anti Infect Ther; 2010 Nov; 8(11):1259-71. PubMed ID: 21073291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Moxifloxacin in the management of exacerbations of chronic bronchitis and COPD.
    Miravitlles M
    Int J Chron Obstruct Pulmon Dis; 2007; 2(3):191-204. PubMed ID: 18229559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of moxifloxacin for community-acquired bacterial pneumonia based on pharmacokinetic analysis.
    Yoshida K; Okimoto N; Kishimoto M; Fukano H; Hara H; Yoneyama H; Moriya O; Kawanishi M; Kimura M; Matsushima T; Niki Y
    J Infect Chemother; 2011 Oct; 17(5):678-85. PubMed ID: 21847518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequency of pathogen occurrence and antimicrobial susceptibility among community-acquired respiratory tract infections in the respiratory surveillance program study: microbiology from the medical office practice environment.
    Pfaller MA; Ehrhardt AF; Jones RN
    Am J Med; 2001 Dec; 111 Suppl 9A():4S-12S; discussion 36S-38S. PubMed ID: 11755437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Moxifloxacin (Avelox): an 8-methoxyquinolone antibacterial with enhanced potency.
    Ball P
    Int J Clin Pract; 2000 Jun; 54(5):329-32. PubMed ID: 10954961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Doxycycline or moxifloxacin for the management of community-acquired pneumonia in the UK?
    Ludlam HA; Enoch DA
    Int J Antimicrob Agents; 2008 Aug; 32(2):101-5. PubMed ID: 18571380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Moxifloxacin (Avelox): a novel fluoroquinolone with a broad spectrum of activity.
    Caeiro JP; Iannini PB
    Expert Rev Anti Infect Ther; 2003 Oct; 1(3):363-70. PubMed ID: 15482134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical perspectives on new antimicrobials: focus on fluoroquinolones.
    Talan DA
    Clin Infect Dis; 2001 Mar; 32 Suppl 1():S64-71. PubMed ID: 11249831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A comparison of moxifloxacin and amoxicillin in the treatment of community-acquired pneumonia in Latin America: results of a multicenter clinical trial].
    Jardim JR; Rico G; de la Roza C; Obispo E; Urueta J; Wolff M; Miravitlles M;
    Arch Bronconeumol; 2003 Sep; 39(9):387-93. PubMed ID: 12975069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Moxifloxacin, a novel extended spectrum fluoroquinolone in the treatment of severe infectious inflammatory diseases].
    Svetukhin AM; Blatun LA; Ukhin SA
    Antibiot Khimioter; 2005; 50(2-3):64-72. PubMed ID: 16308942
    [No Abstract]   [Full Text] [Related]  

  • 16. [New fluoroquinolones: levofloxacin, moxifloxacin and gatifloxacin].
    Hoepelman I
    Ned Tijdschr Geneeskd; 2004 Oct; 148(43):2115-21. PubMed ID: 15553354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Moxifloxacin--a new fluoroquinolone antibacterial.
    Drug Ther Bull; 2004 Aug; 42(8):61-2. PubMed ID: 15310155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A brief review of moxifloxacin in the treatment of elderly patients with community-acquired pneumonia (CAP).
    Ferrara AM
    Clin Interv Aging; 2007; 2(2):179-87. PubMed ID: 18044134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of community-acquired pneumonia with moxifloxacin: a meta-analysis of randomized controlled trials.
    Yuan X; Liang BB; Wang R; Liu YN; Sun CG; Cai Y; Yu XH; Bai N; Zhao TM; Cui JC; Chen LA
    J Chemother; 2012 Oct; 24(5):257-67. PubMed ID: 23182045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Role of moxifloxacin in the treatment of community-acquired pneumonia].
    Máthé A; Tóth K; Kovács G
    Orv Hetil; 2004 Oct; 145(44):2227-30. PubMed ID: 15626167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.